Charles S. Berkman
2020 - Ligand Pharmaceuticals
In 2020, Charles S. Berkman earned a total compensation of $1.9M as Senior Vice President and General Counsel at Ligand Pharmaceuticals, a 4% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $176,767 |
|---|---|
| Option Awards | $675,820 |
| Salary | $441,917 |
| Stock Awards | $644,168 |
| Other | $6,180 |
| Total | $1,944,852 |
Berkman received $675.8K in option awards, accounting for 35% of the total pay in 2020.
Berkman also received $176.8K in non-equity incentive plan, $441.9K in salary, $644.2K in stock awards and $6.2K in other compensation.
Rankings
In 2020, Charles S. Berkman's compensation ranked 5,646th out of 13,090 executives tracked by ExecPay. In other words, Berkman earned more than 56.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,646 out of 13,090 | 57th |
Division Manufacturing | 2,331 out of 5,620 | 59th |
Major group Chemicals And Allied Products | 930 out of 2,253 | 59th |
Industry group Drugs | 804 out of 1,953 | 59th |
Industry Pharmaceutical Preparations | 598 out of 1,458 | 59th |
Source: SEC filing on April 22, 2022.
Berkman's colleagues
We found three more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2020.